Trump says pharma tariffs to come in 2 weeks, signs order to boost domestic output

May 06, 2025 03:37 PM AEST | By Investing

Google News:

Trump says pharma tariffs to come in 2 weeks, signs order to boost domestic output

Recent News

Netflix receives Street-high target at Pivotal Research

3 Takeaways From DaVita CEO Javier Rodriguez on the Future of Health T...

Subaru Releases Seventh Annual Corporate Impact Report

Putting Job Skills to Work for the Greater Good

Investing.com - U.S. President Donald Trump on Monday signed an executive order aimed at boosting domestic pharmaceutical production, and warned that he will soon impose import tariffs on the sector.

Trump’s order will bring down the time taken to approve new pharma plants in the country, and instructs the Food and Drug Administration to streamline reviews while working closely with manufacturers to bring more production capacity online.

The Environmental Protection Agency was also ordered to speed up construction of new facilities.

The move is the latest by Trump to bring more drug manufacturing to the United States. Trump also signaled on Monday that he will slap import tariffs on pharmaceuticals in the next two weeks, after he had earlier this year launched probes into the sector to explore potential trade duties.

Trump has argued that foreign pharma products present a national security risk, due to the U.S.’s heavy reliance on imported drugs and medications.

Pharma tariffs could present significant headwinds to the industry, with the U.S. importing over $200 billion in prescription drugs annually. European companies may be among the worst hit by this trend, along with drug producers in India and medical equipment makers in China.

The threat of U.S. tariffs did see several pharma giants, including Roche (SIX:ROG), Novartis (SIX:NOVN), Eli Lilly (NYSE:LLY) and Johnson&Johnson (NYSE:JNJ) announce increased investments in domestic production over the past few weeks.

Shares in Eli Lilly and Pfizer (NYSE:PFE) were slightly lower in premarket U.S. trading on Tuesday, while Johnson&Johnson’s stock price hovered around the flatline. Elsewhere, several Indian drugmaking firms, especially those with exposure to the U.S., retreated.

Trump’s threat of pharma tariffs marks a fresh development in the president’s aggressive trade agenda. On Sunday, he threatened to impose 100% tariffs on foreign-made films.

This article first appeared in Investing.com

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.